Cladribine Plus Homoharringtonine and Cytarabine Regimen (CHA) for de Novo Acute Myeloid Leukemia
Status:
Recruiting
Trial end date:
2024-08-31
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to evaluate the response and safety of Cladribine plus
Homoharringtonine and Cytarabine regimen (CHA) protocol in de novo acute myeloid leukemia
with age <60y. This is a prospective, single-armed mono-center based investigator-initiated
trial. About 30 patients who meet the enrollment criteria with be treated with CHA as
induction chemotherapy. The complete response rate, survival rate, recurrence rate, and
treatment-related mortality with be observed.